Who qualifies

UPDATED FEB 2026

Part of the Tylenol Autism investigation
People's Justice Research TeamUpdated February 21, 2026Fact-checked

Verified against court and regulatory records · No upfront fees · Your information is never sold

Free Case Review

Check your eligibility — free

Answer 2-3 quick questions to review your potential case.

Free · Confidential · About 2 minutes · A case specialist responds within 1 business day

Your answers are never sold or shared without your consent.

Why There Are No Settlements Yet — And When That May Change

Pharmaceutical defendants do not generally settle until litigation has progressed to a point where trial risk is clear. In the Tylenol autism litigation, the federal MDL was dismissed in August 2024 without any bellwether trials — meaning no jury has yet evaluated the evidence. The Second Circuit appeal, pending since late 2024, must be resolved before the federal case path is clear. State court cases in California and Illinois are in earlier stages. Settlement discussions typically begin in earnest after: (a) plaintiffs survive Daubert or Frye challenges to their causation experts; (b) at least one bellwether case goes to verdict; or (c) the overall litigation scale makes global resolution more attractive than continued defense costs. One or more of these triggering events may occur in 2026, making the current period the best time to evaluate and preserve your claim before any resolution is structured.

Projected Value Ranges by Diagnosis

Based on comparable pharmaceutical mass torts and published neurodevelopmental cost-of-care data, here are projected ranges if the litigation reaches resolution: ADHD-only claims — $75,000 to $250,000 depending on severity and documentation. Level 1 ASD or combined ASD+ADHD with moderate impact — $150,000 to $400,000. Level 2 ASD requiring substantial support — $300,000 to $750,000. Level 3 ASD requiring very substantial support with lifetime care documentation — $500,000 to $1,500,000 or more. These are projections based on comparable cases, not guarantees. The actual resolution values will depend entirely on the litigation outcome, which remains uncertain pending the Second Circuit ruling and state court developments.

What Drives Case Value Up

Factors that increase the value of an individual claim: higher ASD severity level (levels 2 and 3 have higher lifetime care cost documentation); lifetime care cost analysis prepared by a life care planner; strong prenatal exposure documentation (pharmacy records, OB records noting acetaminophen use); neuropsychological testing showing significant cognitive and adaptive behavior impact; early and consistent treatment records demonstrating the extent of functional impairment; economic expert analysis of lifetime earning capacity loss; and claims in plaintiff-favorable jurisdictions (California, Illinois) where Frye standard applies. Claims with all of these factors present the strongest individual valuations.

FAQ

Frequently Asked Questions

12 QUESTIONS

Yes — the litigation is still active on two fronts. First, the federal appeal: the Second Circuit Court of Appeals heard oral arguments on November 17, 2025, reviewing whether Judge Denise Cote's August 2024 dismissal of MDL-3043 was legally correct. Two of three appellate judges openly questioned the dismissal during oral argument — a significant signal that a reversal is possible. A Second Circuit ruling is expected in 2026. Second, state courts: California and Illinois are actively handling acetaminophen-autism cases under the Frye admissibility standard, which is different from and more favorable than the federal Daubert standard that closed the MDL. Families who qualify should consult an attorney now to evaluate their options in both the federal appeal and state court forums.

Dive deeper

Related Guides

1 GUIDE

The full investigation

Part of the Tylenol Autism Investigation